186347-72-8

Basic information

• Product Name: 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS NO: 186347-72-8
• Molecular Formula: C₁₆H₂₁NO₂
• Molecular Weight: 259.34344
• Mol File: 186347-72-8.mol

Chemical Properties

• Boiling Point: 362.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.079±0.06 g/cm3(Predicted)
• PKA: -1.79±0.40(Predicted)
• CAS DataBase Reference: 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester(186347-72-8)
• EPA Substance Registry System: 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester(186347-72-8)

Safety Data

• Hazardous Substances Data: 186347-72-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 43064-12-6 1,2,3,6-tetrahydro-4-phenylpyridine hydrochloride 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 98-80-6 phenylboronic acid 
• 856684-30-5 1-tert-butyloxycarbonyl-4-(diethylphosphoryloxy)-1,2,3,6-tetrahydropyridine 
• 100-59-4 phenylmagnesium chloride 
• 856684-31-6 tert-butyl 4-((diphenoxyphosphoryl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate 
• 936231-05-9 1-(tert-butoxycarbonyl)-4-(benzyldimethylsilanyl)-3,6-dihydro-2H-pyridine 
• 591-50-4 iodobenzene 
• 936231-00-4 1-benzyl-4-(benzyldimethylsilanyl)-1,2,3,6-tetrahydro-pyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 41780-52-3 N’-(1-benzylpiperidin-4-ylidene)-4-methylbenzenesulfonohydrazide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 357608-32-3 (+)-tert-butyl (3R,4R)-3-hydroxy-4-phenylpiperidine-1-carboxylate 
• 357608-33-4 (R,R)-tert-butyl 3-(4-bromo-benzyloxy)-4-phenyl-piperidine-1-carboxylate 
• 923948-71-4 tert-butyl (3R,4R)-3,4-dihydroxy-4-phenyl-piperidine-1-carboxylate 
• 123387-49-5 tert-butyl 4-phenylpiperidine-1-carboxylate 
• 771-99-3 4-phenylpiperidine 
• 41914-43-6 2-(4-phenylpiperidin-1-yl)ethanamine 
• 1394387-97-3 N-((3-isopropylisoxazol-5-yl)methyl)-2-(4-phenylpiperidin-1-yl)ethanamine 
• 39793-35-6 2-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)ethanamine 
• 1394387-82-6 N-((3-isopropylisoxazol-5-yl)methyl)-2-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)ethanamine 

Relevant articles and documents

FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS

The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4- phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Cav3.1 (α 1G) and Cav3.2 (α1H) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of α1G and α1H subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain.

Highly enantioselective organocatalytic oxidative kinetic resolution of secondary alcohols using chiral alkoxyamines as precatalysts: Catalyst structure, active species, and substrate scope

The development and characterization of enantioselective organocatalytic oxidative kinetic resolution (OKR) of racemic secondary alcohols using chiral alkoxyamines as precatalysts are described. A number of chiral alkoxyamines have been synthesized, and their structure-enantioselectivity correlation study in OKR has led us to identify a promising precatalyst, namely, 7-benzyl-3-n-butyl-4-oxa-5-azahomoadamantane, which affords various chiral aliphatic secondary alcohols (ee up to >99%, krel up to 296). In a mechanistic study, chlorine-containing oxoammonium species were identified as the active species generated in situ from the alkoxyamine precatalyst, and it was revealed that the chlorine atom is crucial for high reactivity and enantioselectivity. The present OKR is the first successful example applicable to various unactivated aliphatic secondary alcohols, including heterocyclic alcohols with high enantioselectivity, the synthetic application of which is demonstrated by the synthesis of a bioactive compound.

A versatile palladium catalyst system for Suzuki-Miyaura coupling of alkenyl tosylates and mesylates

A general and effective palladium system for Suzuki-Miyaura coupling of alkenyl electrophiles under mild reaction conditions is reported. With the Pd(OAc)2/CM-phos system, a variety of alkenyl tosylates are coupled well with ArB(OH)2. Moreover, the first successful examples of using alkenyl mesylates in alkenylation are also described.

SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT

Syntheses of unsaturated piperidines from piperidones through a silyl pipehdine reagent via the Shapiro reaction and palladium-catalyzed cross- coupling reactions with organo halides.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Synthesis of 4-arylpiperidines from 1-benzyl-4-piperidone: Application of the shapiro reaction and alkenylsilane cross-coupling

Equation Presented 1-Benzyl-3,4-unsaturated-4-piperidinyl benzyldimethylsilane has been prepared and observed to readily undergo palladium-catalyzed cross-coupling reactions with a variety of aryl iodides and aryl bromides to generate 3,4-unsaturated 4-arylpiperidines, often at ambient temperature.

Synthesis of 4-substituted tetrahydropyridines by cross-coupling of enol phosphates

Enol phosphates, synthesized from 4-piperidone, react by palladium catalyzed cross-coupling with arylboronic acids and by iron and palladium catalyzed cross-coupling with Grignard reagents to give 4-substituted tetrahydropyridines.

Selective iron-catalyzed cross-coupling reactions of Grignard reagents with enol triflates, acid chlorides, and dichloroarenes

Cheap, readily available, air stable, nontoxic, and environmentally benign iron salts such as Fe(acac)3 are excellent precatalysts for the cross-coupling of Grignard reagents with alkenyl triflates and acid chlorides. Moreover, it is shown that dichloroarene and -heteroarene derivatives as the substrates can be selectively monoalkylated by this method. All cross-coupling reactions proceed very rapidly under notably mild conditions and turned out to be compatible with a variety of functional groups in both reaction partners. A detailed analysis of the preparative results suggests that iron-catalyzed C-C bond formations can occur via different pathways. Thus, it is likely that reactions of methylmagnesium halides involve iron-ate complexes as the active components, whereas reactions of Grignard reagents with two or more carbon atoms are effected by highly reduced iron-clusters of the formal composition [Fe(MgX)2]n generated in situ. Control experiments using the ate-complex [Me4Fe]Li2 corroborate this interpretation.

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic